Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Healius Limited ( (AU:HLS) ) has shared an update.
Healius Limited has announced a change in the director’s interest, with Paul Anderson acquiring an additional 54,431 ordinary shares through an on-market trade. This change reflects an increase in Anderson’s indirect interest in the company, potentially signaling confidence in Healius’s future performance and impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited operates in the healthcare industry, providing medical services and facilities across Australia. The company focuses on offering pathology services, diagnostic imaging, and day hospital services, catering to a broad market that includes individual patients, healthcare providers, and government entities.
Average Trading Volume: 4,429,646
Technical Sentiment Signal: Sell
Current Market Cap: A$646.3M
See more data about HLS stock on TipRanks’ Stock Analysis page.